Efficacy

Efficacy, in pharmacology, describes how much biological response a drug produces once it has successfully bound to its target receptor — its intrinsic capacity to activate that receptor, independent of how much drug is required to get there. This is distinct from potency, which is about the quantity needed; two drugs can require the same dose yet differ widely in how strongly they drive a receptor response.

The word carries a second, unrelated meaning in clinical medicine, where efficacy refers to whether a treatment produces its intended effect under controlled study conditions — essentially, does it work? The pharmacological and clinical senses share a name but measure entirely different things. On substance pages here, context will generally make clear which is meant.

How it works · its role

Intrinsic efficacy is best understood as a spectrum. A full agonist binds a receptor and drives it to its maximum possible response. A partial agonist binds the same receptor but can only produce a fraction of that maximum, even when every available receptor is occupied — it has a built-in ceiling that no increase in dose can overcome.

An antagonist carries zero intrinsic efficacy: it occupies the receptor without activating it, simply blocking access to other molecules. An inverse agonist goes further still, suppressing receptor activity below its resting baseline.

These distinctions belong to the drug-receptor pair, not to the drug alone. A compound may act as a full agonist at one receptor subtype and a partial agonist at another, so its net effects depend heavily on which receptors are most relevant at the doses in question.

Relevance to substances & effects

The efficacy concept appears most clearly in opioid pharmacology. Morphine, heroin, and fentanyl are full agonists at the μ-opioid — each can drive a complete response. Buprenorphine, by contrast, is a partial agonist at the same receptor: it produces meaningful analgesic and euphoric effects at lower occupancy, but its ceiling means the response plateaus above a certain dose rather than continuing to climb. This ceiling is central to both its accepted medical use in substance use disorder and its comparatively lower respiratory depression risk.

Across other substance classes, efficacy shapes effect quality as much as effect magnitude. Serotonergic psychedelics act at serotonin receptor subtypes with varying intrinsic efficacies, contributing to why compounds that bind the same receptor can produce meaningfully different perceptual profiles.

Efficacy also matters when substances are combined. A partial agonist competing for the same receptor as a full agonist can blunt the full agonist's effect by occupying sites without activating them fully — a dynamic relevant to opioid combinations and one of the mechanisms underlying some harm reduction pharmacotherapy strategies.